Page 5 - தலையங்கம் கட்டுரை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Editorial Article: Researchers develop a promising new therapy to tackle metabolic liver disease, NASH Dr. Erik Tillman shares his virtual company’s quest to find an effective new life-changing treatment for non-alcoholic steatohepatitis 03 Aug 2021 Dr. Erik Tillman, Principal Scientist at Akero Therapeutics Non-alcohol related fatty liver disease (NAFLD) presents a global health crisis estimated to affect billions of people worldwide, including an estimated 100 million in the US alone 1. In this exclusive interview, we speak with Dr. Erik Tillman, Principal Scientist at Akero Therapeutics, to find out more about Akero’s pioneering work developing treatments for non-alcoholic steatohepatitis (NASH), a severe form of NAFLD that increases the risk for cardiovascular and liver-related morbidity and mortality. Tillman explains how he and his teammates are developing a multi-modal drug that may help treat the drivers of NASH and reverse liver scarring.  Tillman explains how his

Erik tillmanEditorial articlePrincipal scientistAkero therapeuticsSvar life scienceSvar lifeLife scienceNature medicineஏறிக் வரைதலையங்கம் கட்டுரைப்ரிந்ஸிபல் விஞ்ஞானிசுவர் வாழ்க்கை அறிவியல்சுவர் வாழ்க்கைவாழ்க்கை அறிவியல்இயற்கை மருந்து